DoW Breast Cancer, Breakthrough Award Level 4
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 4, 2026
- Amount
- Program total $21M
- Closes
- Sep 30, 2026 (in 13 days)
Similar opportunities open now
- DoW Breast Cancer, Breakthrough Award Level 3Same funderOpenDefense Health Agency Contracting Activity - DHACACloses in 13 days
- DoW Breast Cancer, Transformative Breast Cancer Consortium AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 13 days
- DoW Ovarian Cancer, Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 14 days
- DoW, Peer Reviewed Cancer, Impact AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 18 days
- DoW Peer Reviewed Cancer, Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 18 days
Classification and identifiers
- Solicitation number
- HT942526BCRPBTA4
- Assistance listing (CFDA)
- 12.420
Amount
Program total $21M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Level 4. Distinctive Features: · Clinical trials are required. · The research ...